Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
CONCLUSIONS: There were considerable differences in the proportions of US adults with T2D who met the eligibility criteria for these studies.The DECLARE-TIMI 58 trial criteria were the most generalizable to the US T2D population.
PMID: 29693360 [PubMed - in process]
Source: The American Journal of Managed Care - Category: Health Management Authors: Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB Tags: Am J Manag Care Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Forxiga | Health Management | Heart | Invokana | Jardiance | Managed Care | Nutrition | SGLT2 Inhibitors | Sodium | Study